151 related articles for article (PubMed ID: 25535979)
21. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
[TBL] [Abstract][Full Text] [Related]
22. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
[TBL] [Abstract][Full Text] [Related]
23. Methionine restriction reduces the chemosensitivity of central nervous system tumour cell lines.
Najim N; Podmore ID; McGown A; Estlin EJ
Anticancer Res; 2009 Aug; 29(8):3103-8. PubMed ID: 19661322
[TBL] [Abstract][Full Text] [Related]
24. Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin.
Gupta V; Su YS; Wang W; Kardosh A; Liebes LF; Hofman FM; Schönthal AH; Chen TC
Neurosurg Focus; 2006 Apr; 20(4):E20. PubMed ID: 16709026
[TBL] [Abstract][Full Text] [Related]
25. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
[TBL] [Abstract][Full Text] [Related]
26. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.
Cao VT; Jung TY; Jung S; Jin SG; Moon KS; Kim IY; Kang SS; Park CS; Lee KH; Chae HJ
Neurosurgery; 2009 Nov; 65(5):866-75; discussion 875. PubMed ID: 19834398
[TBL] [Abstract][Full Text] [Related]
27. Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.
Pyko IV; Nakada M; Sabit H; Teng L; Furuyama N; Hayashi Y; Kawakami K; Minamoto T; Fedulau AS; Hamada J
Carcinogenesis; 2013 Oct; 34(10):2206-17. PubMed ID: 23715499
[TBL] [Abstract][Full Text] [Related]
28. HFE polymorphisms influence the response to chemotherapeutic agents via induction of p16INK4A.
Lee SY; Liu S; Mitchell RM; Slagle-Webb B; Hong YS; Sheehan JM; Connor JR
Int J Cancer; 2011 Nov; 129(9):2104-14. PubMed ID: 21190189
[TBL] [Abstract][Full Text] [Related]
29. Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma.
Hsu CY; Lin SC; Ho HL; Chang-Chien YC; Hsu SP; Yen YS; Chen MH; Guo WY; Ho DM
Am J Surg Pathol; 2013 Feb; 37(2):264-71. PubMed ID: 23282970
[TBL] [Abstract][Full Text] [Related]
30. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.
Kitange GJ; Carlson BL; Schroeder MA; Grogan PT; Lamont JD; Decker PA; Wu W; James CD; Sarkaria JN
Neuro Oncol; 2009 Jun; 11(3):281-91. PubMed ID: 18952979
[TBL] [Abstract][Full Text] [Related]
31. Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.
Zhang J; Stevens MF; Laughton CA; Madhusudan S; Bradshaw TD
Oncology; 2010; 78(2):103-14. PubMed ID: 20357518
[TBL] [Abstract][Full Text] [Related]
32. MGMT methylation: a marker of response to temozolomide in low-grade gliomas.
Everhard S; Kaloshi G; Crinière E; Benouaich-Amiel A; Lejeune J; Marie Y; Sanson M; Kujas M; Mokhtari K; Hoang-Xuan K; Delattre JY; Thillet J
Ann Neurol; 2006 Dec; 60(6):740-3. PubMed ID: 17192931
[TBL] [Abstract][Full Text] [Related]
33. In vitro drug response and molecular markers associated with drug resistance in malignant gliomas.
Fruehauf JP; Brem H; Brem S; Sloan A; Barger G; Huang W; Parker R
Clin Cancer Res; 2006 Aug; 12(15):4523-32. PubMed ID: 16899598
[TBL] [Abstract][Full Text] [Related]
34. Folate supplementation limits the aggressiveness of glioma via the remethylation of DNA repeats element and genes governing apoptosis and proliferation.
Hervouet E; Debien E; Campion L; Charbord J; Menanteau J; Vallette FM; Cartron PF
Clin Cancer Res; 2009 May; 15(10):3519-29. PubMed ID: 19451595
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of protracted daily temozolomide for low-grade gliomas in adults.
Kesari S; Schiff D; Drappatz J; LaFrankie D; Doherty L; Macklin EA; Muzikansky A; Santagata S; Ligon KL; Norden AD; Ciampa A; Bradshaw J; Levy B; Radakovic G; Ramakrishna N; Black PM; Wen PY
Clin Cancer Res; 2009 Jan; 15(1):330-7. PubMed ID: 19118062
[TBL] [Abstract][Full Text] [Related]
36. Biological activity of tumor-treating fields in preclinical glioma models.
Silginer M; Weller M; Stupp R; Roth P
Cell Death Dis; 2017 Apr; 8(4):e2753. PubMed ID: 28425987
[TBL] [Abstract][Full Text] [Related]
37. Re-evaluation of cytostatic therapies for meningiomas in vitro.
Wilisch-Neumann A; Pachow D; Wallesch M; Petermann A; Böhmer FD; Kirches E; Mawrin C
J Cancer Res Clin Oncol; 2014 Aug; 140(8):1343-52. PubMed ID: 24816784
[TBL] [Abstract][Full Text] [Related]
38. Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of cytochrome c oxidase bearing the COX4-1 regulatory subunit.
Oliva CR; Zhang W; Langford C; Suto MJ; Griguer CE
Oncotarget; 2017 Jun; 8(23):37568-37583. PubMed ID: 28455961
[TBL] [Abstract][Full Text] [Related]
39. Combined Delivery of Temozolomide and Anti-miR221 PNA Using Mesoporous Silica Nanoparticles Induces Apoptosis in Resistant Glioma Cells.
Bertucci A; Prasetyanto EA; Septiadi D; Manicardi A; Brognara E; Gambari R; Corradini R; De Cola L
Small; 2015 Nov; 11(42):5687-95. PubMed ID: 26395266
[TBL] [Abstract][Full Text] [Related]
40. Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway.
Oliveira-Ferrer L; Hauschild J; Fiedler W; Bokemeyer C; Nippgen J; Celik I; Schuch G
J Exp Clin Cancer Res; 2008 Dec; 27(1):86. PubMed ID: 19114005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]